IDEA Biosciences filed its first rolling NDA for derovacertib in the third quarter and anticipates acceptance in the first half of next year. It plans to start two registrational phase three studies by the end of the year.
IDYA · IDEAYA Biosciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Nov 4, 2024
- Latest filing
- 10-Q · Nov 3
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
IDEAYA Biosciences submitted an NDA to the FDA for the darovasertib combination in metastatic uveal melanoma, stopped enrollment in OptimUM-010, and reported approximately $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.
IDEAYA Biosciences completed its darovasertib NDA submission, stopped enrollment in OptimUM-010 to save $100-125 million, and reported a $125.7 million net loss with $1.15 billion in cash and marketable securities at September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | 1.24B | As of June 30, 2026 | — |
| Common stock sold under at-the-market offering program | 1,196,423 | the three months ended June 30, 2026 filing | — |
| Net proceeds from sale of common stock through at-the-market offering program | $33.1M | Quarter ended June 30, 2026 | — |
| Net proceeds from underwritten public offering and pre-funded warrants | $323.4M | Quarter ended June 30, 2026 | — |
| Remaining balance for research and development services performance obligations | $147M | As of June 30, 2026 | — |
| Total stock compensation expense | $16.7M | Three months ended June 30, 2026 | — |
| Weighted average sales price per share under at-the-market offering | $28.38 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IDYA
this stock
IDEAYA Biosciences, Inc.
|
$2.47B | -26.1% | +3024.4% | — | 8.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 27
IDEA Biosciences filed its first rolling NDA for derovacertib in the third quarter and anticipates acceptance in the first half of next year. It plans to start two registrational phase three studies by the end of the year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IDYA | -19.7% | -26.4% | -8.3% | -20.0% | -26.1% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -11.1% | -17.1% | +0.9% | -11.3% | -27.2% |